Clinical trial
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
NCT00003959 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003959 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome |
| Official title | Vaccination of Patients With Myelodysplastic Syndrome Against Mutated RAS Proteins: A Pilot Trial |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | ras peptide cancer vaccine, sargramostim |
| Enrollment | 1 |
| Start date | Jun 1, 1999 |
| Primary completion | Dec 1, 2001 |
| First posted | Mar 15, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: